|
|
|
|
|
Pyridostigmine
drug data and news
Pyridostigmine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pyridostigmine | ||
| Brand Names/Synonyms | CHEMBANK860; Mestinon; P142; PYRIDOSTIGMINE; Pyridine N-Oxide; Pyridostigmine; Pyridostigmine Bromide; Pyridostigmine Bromine; Pyridostigminum; Regonol | ||
| Indication | For the treatment of myasthenia gravis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Pyridostigmine is used to treat muscle weakness in people with myasthenia gravis and to combat the effects of curariform drug toxicity. It also has a military use as a nerve gas antidote. | ||
| Mechanism Of Action | Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine. | ||
| Pyridostigmine News (When available) |
| ||
| Dosage Forms | LIQUID; TABLET; TABLET (EXTENDED-RELEASE); SYRUP | ||
| Drug_Category | Antimyasthenics; Anticholinergic Agents; Cholinesterase Inhibitors; Parasympathomimetics; ATC:N07AA02 | ||
| Absorption | Poorly absorbed from the GI tract | ||
| Interactions |
Interactions for Pyridostigmine: No Information Provided. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | (1-methylpyridin-5-yl) dimethylaminoformate | ||
| Chemical Formula | C9H13N2O2 | ||
| Molecular Weight | 181.212 g/mol | ||
| Smiles String | C[N+]1=CC=CC(=C1)OC(=O)N(C)C | ||
| Melting Point | 153 °C | ||
| Water Solubility | Freely soluble in water | ||
| State | Solid | ||
| LogP/Hphobicity | 1.554 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hydrolysis by cholinesterases and by liver | ||
| Half Life | 3 hours following oral administration | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pyridostigmine.html http://www.rxlist.com/cgi/generic2/pyridostigmine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00380 | ||
| CAS Registry Number | 155-97-5 | ||
| KEGG Compound ID | D00487 | ||
| PubChem ID | CID:4991 | ||
| PharmGKB ID | PA451185 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 869953 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |